title: Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients.
abstract: Circulating bone marrow derived immature cells, including CD34-positive (CD34(+)) cells, contribute to maintenance of the vasculature, not only as a pool of endothelial progenitor cells (EPCs), but also as a source of growth/angiogenesis factor. We hypothesized that the thiazolidineone compound pioglitazone could stimulate the circulating CD34(+) cells in diabetic patients. Thirty-four patients with type 2 diabetes received 15-30 mg pioglitazone for 24 weeks. The number of circulating CD34(+) cells significantly increased at 12 and continued this effect for 24 weeks (1.08+/-0.39, 1.34+/-0.34 and 1.32+/-0.28cells/microl at 0, 12 and 24 weeks, respectively). The change of CD34(+) cell levels (DeltaCD34(+) cells) between 0 and 12 weeks was significantly correlated with the change of high sensitive C reactive protein levels (Deltahs-CRP) and change in adiponectin levels (Deltaadiponectin) (r=-0.412, r=0.359, respectively). Our study demonstrated that pioglitazone treatment increased circulating CD34(+) cells, suggesting that this effect may at least partly contribute to the anti-atherosclerotic action of pioglitazone.
authors.affiliation: Department of Atherosclerosis and Diabetes, National Cardiovascular Center, Suita, Osaka, Japan. makinoh@hsp.ncvc.go.jp
authors.forename: Hisashi
authors.initials: H
authors.lastname: Makino
authors.forename: Sadanori
authors.initials: S
authors.lastname: Okada
authors.forename: Ayako
authors.initials: A
authors.lastname: Nagumo
authors.forename: Takako
authors.initials: T
authors.lastname: Sugisawa
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kishimoto
authors.forename: Taura K
authors.initials: TK
authors.lastname: Akie
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Soma
authors.forename: Akihiko
authors.initials: A
authors.lastname: Taguchi
authors.forename: Yasunao
authors.initials: Y
authors.lastname: Yoshimasa
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D000077205:Pioglitazone